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Introduction
Migraines  are  common  illnesses.  Studies  conducted  in 12
Latin  American  cities,  including  two  in Mexico,  have  found
that  its  prevalence  in  our  country  is  15%.  The  rate  in gender
is  3:1  (Women/Men)  worldwide.
The  diagnostic  criteria  for  migraines  were  published  for
the  first  time  in 1988,  in the first  edition  of the  International
Headache  Classification,  promoted  by the  International
Headache  Society,  with  its  second  edition  in 2003,  and
a  third  beta version  that  will probably  be  published  in
2015.  Diagnostic  criteria  for  the  different  forms  of migraines
were  first  described  in this  document,  which  has simplified
communication  among doctors  and  made  possible  compar-
isons  between  studies.  The  current  migraine  criteria  (with
and  without  aura)  are shown  in  Table  1.
As  in  all  primary  headaches,  paraclinic  and  imaging  stud-
ies  are  normal  and rarely  necessary,  exception  made  for  the
cases  where  there  is  clinical  doubt  or  whenever  the patient
is  too  anxious  and  wishes  to  be  ‘‘as certain  as  you can  be’’.
This  may  be  a valid  reason;  however  it  may  increase  the cost
of  medical  attention  and  can be  problematic  in institutions
with  a  high  volume of  patients.
The  management  of migraines  must  contemplate  two
aspects:
1.  Acute  management  (abortive).
2. Preventive  management.
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In  both  cases,  the following  pharmacological  and  non-
pharmacological  measures  must  be contemplated.
Management generalities
Before  beginning  management  of a migraine,  as  in any  other
pathological  entity,  we  must  ask  ourselves,  several  ques-
tions:
1.  Are  medications  necessary?
2.  If so, are there  parameters  to  choose  one  as  the best?
3.  How will  results  be  measured?
4.  Which  will  the success  and  failure  criteria  be  to decide
a  change  in  management?  In  other  words,  how  long  to
maintain  a  medication  before  considering  it did  not work.
5.  How long  will  a  successful  treatment  last?
6. What is  the a  priori  probability  of  recovery/recurrence?
Answering  each  and  every  one  of  these  questions  before
beginning  management  is  fundamental.  It  gives  the  man-
agement  sense  and  direction,  for both  the doctor  as well
as  the  patient.  Additionally,  it brings  the patient  the feel-
ing  that  he/she  is  able  to  do something,  or  cooperate  in the
treatment,  and thus  the patient  perceives  he/she  has  some
control  over  his/her  illness.
Abortive management
General  guidelines:
1.  To  treat as  early  as  possible.  The  instruction  is:  ‘‘Take  the
medication,  or  do  as  indicated,  as  soon  as  the patient
recognizes  if a crisis  arises.’’  Patients  learn  to  recog-
nize  when this happens,  and we  know  that  abortive
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Table  1  Diagnostic  criteria  of  frequent  migraines.
Migraine  without  aura
A. At  least  five  attacksfulfilling  criteria  B--D
B. Headache  attacks  lasting  4--72  hours  (untreated  or  unsuccessfully  treated)
C. Headache  has  at least  two  of  the  following  four  characteristics:
1. unilateral  location
2. pulsating  quality
3. moderate  or  severe  pain  intensity
4. aggravation  by  or  causing  avoidance  of  routine  physical  activity  (e.g.  walking  or  climbing  stairs)
D. During  headache  at least  one  of  the  following:
1. nausea  and/or  vomiting
2.  Photophobia  and  phonophobia
E. Not  better  accounted  for  by  another  ICHD-3  diagnosis.
Migraine  with  Aura
A.  At  least  two  attacks  fulfilling  criteria  B and  C
B. One  or  more  of  the  following  fully  reversible  aura  symptoms:
1. visual
2.  sensory
3.  speech  and/or  language
4.  motor
5.  brainstem
6.  retinal
C. At  least  two  of  the  following  four  characteristics:
1. one  aura  symptom  spreads  gradually  over  5 minutes,  and/or  two  or  more  occur  in succession
2. each  individual  aura  symptom  lasts  5--60  minutes
3. at  least  one  aura  symptom  is unilateral
4. the  aura  is  accompanied,  or  followed  within  60  minutes,  by  headache
D. Not  better  accounted  for  by  another  ICHD-3  diagnosis,  and  transient  ischaemic  attack  has  been  excluded.
treatment  loses  effect  in a  direct  proportion  to  the delay
in  treatment.
2.  To  have  a  record  of  the  amount  of  analgesic  used.  Set
limits  and  have  a  ‘‘plan  B’’  and  ‘‘plan  C’’  ready  in case
of  acute  therapeutic  failure.
3.  If  we  are  going  to  try a  medication  (i.e. a  triptan),  try
it  in  at  least  two  crises  before  declaring  therapeutic
failure.
4.  Remember  that  the abortive  treatment  is  exactly  that:
abortive.  Although  there  are  exceptions;  it must  not be
used  with  a  schedule.  The  principle  is  to  NEVER  give
abortive  medication  on  a  schedule.  Exceptions  would be
situations  where  we  can  anticipate  the  onset  of the crisis,
like  migraines  associated  with  menstruation  (with  regu-
lar  cycles)  or  episodic  cluster  headache.  In  general,  the
evolution  of  the crisis  in most  migraines  is  predictable;
thus  the  patient  is  able  to  know  when to  take  the
medication.
Non-pharmacological  measures
Some  patients  learn  some techniques  which  can  help  attenu-
ate  the  pain  or  make  it disappear.  The  most  utilized  method
is  sleep.  The  physician  can  try  to  compress  both  superficial
temporal  arteries  in front  of  the  tragus  (or  on  the  side  where
there  is  pain,  if it is  hemicranial)  in order  to  try  to  abort  the
crisis.  Its  effectiveness  is  estimated  to be between  30%  and
40%.
Diet is  reserved  for  those  cases  where  there  is a  close
temporal  relationship  between  the  dietary  element  imputed
and the  onset  of the  crisis.  There  is no  point  in giv-
ing  a  restrictive  diet  a  priori. The  idea  of  prohibiting
the  consumption  of specific  food,  like chocolate,  cheese,
canned  foods,  sausages,  Chinese  food,  wine  (especially  red)
or  any  form  of  alcohol,  among  others,  is  highly  popu-
lar.  The  experience  in our  center  is  that  food  trigger  are
rare.
A  careful  interrogatory  is  the best  tool  to  indicate
a  restrictive  diet.  Therefore,  it is  mandatory  to  keep
a  headache  diary  where  the  patient  must  record  the
number  of  attacks,  intensity,  time,  response  to  medica-
tions,  and relationship  to  external  events  or  foods.  This
diary  will  give  us the parameters  to  make  changes  in
management.
Medications
The  best results  of abortive  treatment  are  with  medica-
tions.  Individual  sensitivity  to a  medication  is  unpredictable;
however,  we  have  probabilities  of  effectiveness.  The  most
effective  medications  are triptans,  and  within  this  group,
rizatriptan  and  eletriptan  have  the  most  favorable  evidence.
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However,  there  is  no  way  of  predicting  the  result  of  a  partic-
ular  medication  in a  particular  patient.  Furthermore,  failure
of  one  triptan  does not predict  the failure  of another,  thus
trying  out  two  or  three  different  triptans  may  be justi-
fied.  Our  protocol  is  to  start  with  one  of  these two,  to
try  it  for  at least  2  crises,  and  decide  whether  or  not
they  worked.  If they  did not  work,  switch  to  a  different
triptan.  The  instruction  to  the  patient  is:  take  (or  place
the  wafer  of rizatriptan  or  zolmitriptan  over/under  the
tongue)  the medication  as  soon  as  the  patient  recognizes
the  onset of  a crisis.  Keep  in  mind  that the effectiveness
of  the  medication  decreases  with  the interval  before  tak-
ing  it;  once  the first  dosage  of medication  is  taken  we ask
them  to  wait  for  an hour;  if  at  the end  of  the hour  the
crisis  is  not  over,  take  the second  dose.  If  after  the sec-
ond  hour  (an  hour  after  the second  dose),  the crisis  has
not  disappeared,  begin  with  a second,  different,  medica-
tion.  The  concept  of ‘‘crisis  disappearance’’  is  precisely
that:  to  completely  stop  not  only the pain  (which  should
completely  disappear),  but  also  the autonomic  and cog-
nitive  symptoms,  etc.  If residual  symptoms  persist,  the
probability  of recurrence  is  greater.  Recurrence  is  defined
as  the  reappearance  of  a crisis  in a period  shorter  than
24  h  from  treatment.  It is  important  to  remember  that  all
abortive  medications,  if used  frequently,  can cause  rebound
headaches.  Thus  the  need  to  keep  track  of  any  medication
that  the  patient  may  take,  even  if  they  are over-the-counter
medications.
Ergotamine  is  also  effective  and low-cost,  making  it
a  good  option  for institutions  with  a high  volume  of
patients.  It  has  an effectiveness  of  40--60%  in pain  reduc-
tion/disappearance.  The  main  problem  is  that  it is  highly
addictive  and  we  must  take  all  precautions  when utiliz-
ing  potentially  addictive  drugs:  keep  track  of  medication,
supervise  prescriptions,  and  review  results  frequently.  Indi-
cations  to  the  patient  are:  initiate  treatment  as  soon  as  a
crisis  is  recognized;  start with  1 mg of  the usual presenta-
tions  (two  tablets  of  0.5  mg)  and  give  an additional  0.5 mg
every  half  hour  until  one of  these three  things  occur:  the
crisis  aborts,  the patient  starts  vomiting,  or  6  tablets  (3 mg)
are  taken.  The  consumption  of  more  than  6  tablets  in  a 24  h
period,  or 16 (8 mg)  in  a week  is  the threshold  to  develop
rebound  headaches,  in  addition  to  increasing  the  risk  of
addiction.  If the  episode  ceases  at,  let  us suppose,  2 mg
(four  tablets),  and  the  pain  returns  within  the  following  24  h,
medication  will  be  given  to  the patient  ‘‘as  if it were  the
next  half  an hour’’  If longer,  it  will  be  considered  as  a  new
episode.
Over-the-counter  medications  are  commonly  utilized,
motu  proprio,  by  patients.  Many  learn  that  certain  med-
ications  or a  combination  of  analgesics  give  them relief
or  abort  the  crisis.  The  problem  with  self-medication  is
that  it  is the single  most  important  factor  for chronifica-
tion  and  the transformation  of  an  episodic  migraine  to  a
chronic  one.  There  will  always  be  the need  to  investigate
the  use,  dosage,  frequency,  etc. of such self-medication.
The  same  principle  applies  with  ‘‘natural’’  medications  or
herbal  medicine.  The  physician  should  intentionally  ask  for
their  use  because  there  may  be  active  pharmacological  prin-
ciples  that  can  complicate  the  evolution  or  result  of the
treatment.
Table  2  Level  of  evidence  for  preventive  medicines.
Level  A:  Medications  with  a  well-established  efficiency
(≥2 Class  1 clinical  trials)
A. Antiepileptics:  Divalproex  sodium,  topiramate
sodium  valproate
B. Beta  blockers:  metoprolol,  propranolol,  timolol
C.  Triptans:  frovatriptan
Level  B:  Medications  that  are  likely  to  be effective  (1
class 1 study/2  class  2  studies)
A. Antidepressants/SISRs/SISNRs/ATT:  Amitriptyline,
venlafaxine
B.  Beta  blockers:  atenolol,  nadolol
C.  Triptans:  naratriptan,  zolmitriptan
Level  C:  Possibly  effective  medications  (one  class  2
study)
A. ACEIs:  lisinopril
B.  ARAs:  candesartan
C.  Alpha  agonists:  clonidine,  guaifenesin
D. Antiepileptics:  carbamazepina
E. Beta  blockers:  nebivolol,  pindolol
F. Antihistamines:  cirpoheptadina
Level  U:  Insufficient  or  inadequate  data  to  make
recommendations
A. Carbonic  anhydrase  inhibitor:  acetazolamide
B. Antithrombotics:  acenocoumarol,  coumadin,
picotamide
C. Antidepressants  SISRs/SISNRs:  fluvoxamine,
fluoxetine
D. Antiepileptics:  gabapentin
E. Tricyclics:  protriptyline
F. Beta  blockers:  bisoprolol
G.  Ca  channel  blockers:  nicardipine,  nifedipine,
nimodipine,  verapamil
H.  Vascular  smooth  muscle  relaxants:  cyclandelate
Other:  Medications  established  as  possibly/probably
ineffective
A. Established  as  ineffective:  lamotrigine
B.  Probably  ineffective:  clomipramine
C.  Possibly  ineffective:  acebutolol,  clonazepam,
nabumetone,  oxcarbazepine,  telmisartan
ACEIs: angiotensin converting enzyme inhibitors; ARAs:
angiotensin receptor antagonists; SISRs: selective inhibitors of
serotonin recovery; SISNR: selective inhibitors of serotonin and
norepinephrine recovery.
It is  important  to  keep  in mind  that  the ideal  objective  of
treatment  is  not  to  use  abortive  medications,  because  there
are  no  more  episodes.
It  is  important  not  to  mix ergotamines  and  triptans  in the
same  session  of treatment.  It  is a paramount  contraindica-
tion  that  one  must  keep  in mind.
Preventive treatment
There  are  publications  of international  guidelines  for
preventive  management  of  episodic  migraines  with  medi-
cations.  Table  2 shows  the different  groups  of  drugs  with
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their  levels  of  evidence  from the  American  Academy  of  Neu-
rology  guidelines, 1 that  in  general  agree  with  the  rest  of
international  organizations.
In our  country  there  is  no  hard data  on  the  effec-
tiveness  of medications  in our  population,  however  there
is  some  useful  information.  In 2005,  the Headache  Study
Group  of  the Mexican  Academy  of  Neurology  published
a  consensus  on the management  of migraines.  Combin-
ing  experiences,  we  proposed  that  our  population  required
lower  doses  than  those  published.  This  data  has  been com-
mented  on international  meetings  and  our  colleagues  in
Latin  America  and Spain  concur  with  the impression  that  the
doses  generally  needed  in our  respective  populations  are
lower.  Regarding  the preferences  of medications,  in 2008
our  group  conducted  a national  survey  on  the  behavior  of
neurologists  and  neuropediatricians  in  the  management  of
migraines.2
Non  pharmacological  treatment
As  mentioned  above,  one  must  identify  the  individual  trigg-
ering  factors,  should there  exist.  Even  though  they  are
not  very  frequent,  they  can  be: dietary  elements,  lack
or  excess  of  sleep,  irregular  meal times,  and exposure  to
intense  light.  The  causal  relationship  between  stress  and
the  production  of  a crisis  is  hard  to  prove,  even  if  it is
an  idea  that  ‘‘sounds  good’’.  Obesity  has  been  proven
as  a  risk  factor  for  migraine  chronification  and  dimin-
ished  response  to  medication.  Thus  it is  recommended,
as  in  other  situations,  to  comply  with  general  rules  of
hygiene.
Preventive  medications
In  Table  2 there  is  a  list  of  medications  with  better  evidence.
The  recommendations  for non-neurologists  are:
1.  Always  keep  a ‘‘headache  diary’’  recording  the  number
of  crises,  intensity,  duration,  time,  associated  symp-
toms,  triggers,  effect  of  used medications,  unwanted
or  adverse  effects,  need  of  rescue  medication  and  days
without  pain.  It is  fundamental  in order  to  assess  the
result  of  the  treatment.  Aside  from  this,  the  MIDAS
scale  can  be  used  to  assess  the impact  of the  disease
on  activities  of  daily  living.
2. There  are  no  specific  guidelines  or  criteria  to  start  a
preventive  treatment.  In  general,  we  take  into  account
the  number  of  crises  and  the impact  on  quality  of  life.
With  two  or  more  crises  per  month  the risk/benefit  ratio
of  medications  is  considered  satisfactory  to  justify  the
beginning  of  treatment.  In  some people  (i.e.  women
with  migraines  associated  with  menstruation  and  reg-
ular  cycles)  we  are able  to  begin  ‘‘short  preventive
treatments’’,  three  days  before  and  after  the expected
onset  of  the  crisis,  in  each  cycle.  The  same  happens  in
other  types  of  headaches  where  we  are able  to  predict
the  onset  of a  crisis.
3. Learn  to  manage  two  or  three  medications  well.  Prefer-
ably  from  two  different  groups.
4. Consider  comorbidities.  Rule  out if the patient  is
hypertensive,  suffers  from  asthma,  anxiety,  depression,
obesity  or  other  conditions  that  may  indicate  or  con-
traindicate  a specific  medication.
5. Encourage  the patient  to  comply  with  non-
pharmacological  measures:  enough  sleep,  regular
meal  schedules,  weight  loss,  regular  exercise,  avoiding
excesses  of  food,  drinks  and  alcohol  and  other  general
hygiene  measures.
6.  Establish,  along  with  the  patient,  a treatment  plan with
specific  measurable  goals  and  commit  him  to  accom-
plishing  them.  The  incidence  of  non  compliance  or
abandonment  of  treatments  is  high  and  should  always
be  investigated  in each visit, since  it  may  be a  cause of
therapeutic  failure.
7. There  is  not a guideline  or  specific  evidence  on  the
duration  of a successful  treatment.  The  intervals  vary.
In  our  national  survey,  most  neurologists  and  pedia-
tricians  considered  maintaining  a successful  treatment
for  6--8 months.  However,  there  were  responses  from
3  to  12  months.  In  general,  a  treatment  is  planned
to  last  8 months  without  a crisis. The  first  two
months  are useful to  assess  the  effectiveness  of  the
medication.
8.  At  the beginning  of  treatment  we  know  there  is  a prob-
ability  of effectiveness.  We  must  maintain  the  use  of
a  medication  for  at least  two  months  at  proper  doses
before  deciding  it is  not working.  A frequent  cause  of
‘‘treatment  failure’’ is  not  giving  it enough  time  to
work.  This  should  be clearly  explained  to  the  patient
so that  he/she  cooperates  during  this  period  and  exert
enough  patience.
9.  At  the  end  of the  planned  period,  stop  the  medication
and  observe.  The  rate  of  recurrence  is  30--40%.
10.  While the  goal  is  zero  crises,  sometimes  a few  may  be
tolerated,  either  because  of  low  tolerability  of  the  med-
ication  or  because  the  patient  is  reluctant  to  increase
the  dose.  In these  cases  there  are  no specific  num-
bers  about  the  cure/recurrence  rate  after  completing
a  treatment.  We  must  explain  to  the patient  that
migraines  are  diseases  that  tend  to  recur  in different
epochs  in life.
11. In case  of  recurrence  after  a successful  treatment
(months  or  years  later),  the most  reasonable  thing  to
do  is  to restart  the treatment  which  was  useful.
Migraines  are a condition  which  can be  controlled  and,
sometimes  ‘‘cured’’.  We  ought  to  understand  that  the
concept  of  curing  is  similar  to  that  of other  chronic
conditions  of difficult  prognosis  (rheumatics,  oncological,
etc.),  which  is  the  absence  of  recurrence  in a  deter-
mined  period  of time  after  treatment.  The  doctor  should
pay  attention  to  the details  of  the treatment  in order
to  communicate  to  the patient  what  he is  trying  to
be  accomplish,  and thus  be able  to  gain  his  trust  and
cooperation.
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